GLP-1 Shortage Tracker (2026): FDA Status by Drug and Dose

By Kaden Coziar, Founder and Managing Editor · The RX Index Research

Last verified: August 5, 2026 · United States data · Next full review: September 2026

Disclosure: The RX Index is reader-supported. Some pages on this site contain affiliate links. This page’s shortage labels, source choices, table order, and conclusions are not influenced by commissions. Provider options appear only after the shortage data, refill steps, regulatory explanation, and methodology.

As of August 5, 2026, liraglutide injection is the GLP-1 active ingredient currently listed in shortage by FDA. Even there, six of the nine listed packages are marked Available, while three are marked Limited Availability. Semaglutide injection and tirzepatide injection are nationally resolved. Former Rybelsus 3 mg, 7 mg, and 14 mg packages are listed as discontinued—not as a current shortage.

That is the national answer. This GLP-1 shortage tracker breaks it down by drug, brand, package, and NDC because “FDA says the shortage is over” and “my pharmacy cannot fill it” can both be true at the same time.

FDA decides whether total United States supply can cover total United States demand. It does not decide whether your pharmacy has your exact package on its shelf today. Once you separate national status, package-level status, and local pharmacy availability, the contradiction stops looking mysterious and starts becoming a problem you can troubleshoot.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Where GLP-1 supply stands right now

Sources: FDA Drug Shortages Database, FDA semaglutide and tirzepatide shortage determinations, and an attributed ASHP dulaglutide bulletin. All checked August 5, 2026.

Check my exact drug and package

This tracker is for you if…

* You have a United States prescription and your pharmacy said “out,” “backordered,” or “we cannot order it.”

* You want to know whether the problem is national, package-specific, or local.

* You saw a headline saying the shortage ended, but your pharmacy still cannot fill your prescription.

* You need to know whether a product was discontinued instead of temporarily short.

This tracker is not…

* A promise that a box is on a shelf near you today.

* Advice to change, skip, split, combine, or restart a dose.

* A substitute for your prescriber or pharmacist.

* A tracker for countries outside the United States.

* A direct pharmacy-inventory feed.

---

What is the biggest limitation of this GLP-1 shortage tracker?

This page cannot tell you whether a specific pharmacy has your medication right now. FDA evaluates national supply, and The RX Index does not have a direct live-inventory feed covering every pharmacy.

Any tracker promising “live inventory” needs either a current pharmacy data feed or a recent confirmation from the pharmacy. Without that, “in stock near you” is an estimate, a user report, or a guess dressed up as data.

We do not guess.

Because we refuse to invent a local availability number, every shortage result on this page is tied to a source you can inspect. Every package-level status includes its NDC. Every official status includes a source date. Where the official record is stale or incomplete, we show the gap instead of filling it with a confident-sounding sentence.

If you need guaranteed shelf inventory, this page cannot give you that. If you need to understand what is nationally short, what is package-specific, what was discontinued, and what to ask next, that is exactly what this page is built to do.

---

Why does my pharmacy say it is out if FDA says the shortage is resolved?

A national shortage and an empty pharmacy shelf are two different problems. FDA gives a drug “Resolved” status when the market is considered covered—meaning supply from at least one manufacturer can cover total market demand—even though some manufacturers may still lack particular presentations.

That definition explains most of the apparent contradiction.

“Resolved” is a statement about the national market. It is not a promise about every:

* Manufacturer

* Brand

* Dosage form

* Strength

* Package

* NDC

* Wholesaler

* Pharmacy

* ZIP code

A pharmacy can still encounter an ordering delay, wholesaler backorder, allocation limit, insurance-network restriction, mail-order problem, refrigerated-storage constraint, or demand spike at one location.

The three layers of GLP-1 availability

Almost every argument about GLP-1 shortages is really two people talking about different layers.

Layer 1 — National status. Can total United States supply meet total United States demand? FDA makes this determination.

Layer 2 — Package status. Is one specific manufacturer’s dosage form, strength, device, package, and NDC listed as available, limited, or discontinued?

Layer 3 — Local availability. Does one pharmacy have that exact package available or orderable today?

Your pharmacy being out proves that there is a problem at Layer 3. It does not, by itself, prove that Layer 1 has returned to national shortage.

Where simplified trackers go wrong

Liraglutide is listed as Currently in Shortage. Liraglutide is used in Saxenda, Victoza, and generic products. A simplified tracker can take that ingredient-level label and paint every liraglutide product red.

FDA’s package-level record says something more useful:

* Saxenda is listed Available.

* Two Victoza packages are listed Limited Availability.

* Five generic packages are listed Available.

* One generic package is listed Limited Availability.

That is why this page never turns one ingredient-level label into a blanket statement about every brand and package.

For a patient, the difference matters. “Liraglutide is in shortage” is nationally accurate but incomplete. “Your exact Saxenda package is listed available by FDA, though your pharmacy may still be out” is the decision-grade answer.

Show me what to ask my pharmacy

---

Why does this feel so confusing?

The gap between the official answer and your lived experience is real. Being told “there is no shortage” while standing at a pharmacy counter that cannot fill the prescription feels like someone is denying what is happening in front of you.

The two statements can both be true:

The national market can be covered while your pharmacy is still unable to obtain your exact product.

The official systems also use labels that sound more definitive than they are. “Available” is not a shelf check. “Resolved” does not mean every package is flowing normally. “Discontinued” is not the same as “backordered.” “Limited Availability” does not mean every pharmacy is empty.

You are not being dramatic. You are looking at different parts of a supply chain that the public databases were not designed to explain in one consumer-friendly result.

---

The right GLP-1 path is not the same for everyone

The right GLP-1 provider is not the same for everyone—it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path, and your budget. Because a general answer cannot resolve those for you, use The RX Index’s Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

Get my personalized GLP-1 action plan

---

Which GLP-1 drugs are in shortage right now?

Liraglutide injection is currently listed by FDA as being in shortage. Semaglutide injection and tirzepatide injection have national shortage-resolution determinations. Dulaglutide does not appear on FDA’s active shortage list, while ASHP’s current dulaglutide bulletin lists the reviewed Trulicity strengths as available.

The package-level detail is where the answer becomes useful.

Liraglutide: six of nine listed packages are available

The table below reconciles every package on FDA’s current liraglutide injection record. It combines manufacturer, NDC, availability, stated reason, recovery estimate, and the date FDA says the manufacturer’s information was reverified.

Original RX Index finding: Six of FDA’s nine listed liraglutide packages are marked Available. Three are marked Limited Availability. None of the nine rows is labeled completely unavailable.

That does not mean two-thirds of all nationwide liraglutide units are available. Package count is not prescription volume, market share, wholesaler inventory, or pharmacy stock. It means exactly what the table says: six of nine FDA-listed presentations carry an “Available” label.

The weight-management brand Saxenda is one of those six.

The recovery estimate that has already passed

FDA lists an estimated recovery of July 2026 for Meitheal NDC 71288-563-85. That estimate has passed, but the company information displayed in the FDA record remains dated June 1, 2026 and the package is still labeled Limited Availability.

We are not treating the estimate as proof that the package recovered.

The precise status is:

The manufacturer’s posted estimate was July 2026. When checked August 5, 2026, FDA’s record still labeled the package Limited Availability and did not display a later reverification confirming recovery.

That is different from saying the estimate failed. It means the public record had not yet confirmed an updated result.

One drug record contains three different information ages

FDA reverifies each manufacturer separately. The same liraglutide record contains:

* Hikma information reverified July 13, 2026

* Meitheal information reverified June 1, 2026

* Novo Nordisk information reverified June 8, 2026

That is a spread of 42 days between the oldest and newest manufacturer reverification dates as of August 5.

Original RX Index finding: A page-level “checked today” date cannot replace row-level source dates. One official shortage page can contain manufacturer information of materially different ages.

That is why every package row above retains its own reverification date.

Why the NDC matters

An NDC is the identifier attached to a particular drug package. Two boxes can contain the same ingredient and strength while having different NDCs because the manufacturer, package size, device, or distribution arrangement differs.

When you call a pharmacy, “liraglutide” may not be specific enough. The NDC on the prescription, box, or pharmacy record can separate an available package from a limited or discontinued one.

Find my exact liraglutide package

---

Is Saxenda in shortage?

Liraglutide injection is nationally in shortage, but FDA lists the Saxenda package in its current record as Available. That is why “Saxenda is in shortage” is too vague to guide a refill decision.

The exact FDA row is:

This does not guarantee your pharmacy has Saxenda. It means FDA’s package-level record does not support claiming that this presentation is currently unavailable nationwide.

When a pharmacy cannot fill Saxenda, ask whether:

1. The exact NDC is out at that store.
2. The wholesaler can order it.
3. Another location can see stock.
4. The issue is supply or an insurance-network restriction.
5. A prescription or authorization problem is being described as an inventory problem.

The useful answer is not “yes” or “no” at the brand level. The useful answer is: the ingredient remains nationally short, the listed Saxenda package is marked available, and your local result still needs to be checked.

---

Is Victoza in shortage?

FDA lists both reviewed Victoza packages as having Limited Availability because of shipping delays. The record gives no recovery date and states that the estimated shortage duration is TBD.

This is a stronger package-specific restriction than the current Saxenda row.

Ask the pharmacy to identify which NDC it is trying to obtain. If the prescription can be filled only with one package because of quantity, device, billing, or plan requirements, calling about “Victoza” generally may produce an incomplete answer.

Do not change package, dose, or product based only on this table. A pharmacist or prescriber needs to confirm what can be dispensed under the prescription.

---

Are generic liraglutide packages available?

Five of the six generic liraglutide packages in FDA’s active record are listed Available. One Meitheal package is listed Limited Availability.

Original RX Index finding: The current generic package split is five available to one limited—not a single yes-or-no generic liraglutide status.

If your pharmacy says “generic liraglutide is unavailable,” ask which manufacturer and NDC it checked. Another listed package may carry a different official status, although the pharmacy, prescription, insurer, and prescriber still determine whether that package can actually be used.

---

Is Ozempic in shortage?

Ozempic injection is not in a current national semaglutide injection shortage. FDA determined on February 21, 2025 that the semaglutide injection shortage was resolved.

FDA also said localized supply disruptions could continue as products moved through the supply chain. That warning matters because a national resolution does not make every pharmacy’s stock level identical.

The shortage began in 2022 and was driven by increased demand. FDA’s resolution decision was based on national supply and demand information—not a claim that every dose would be available at every pharmacy every day.

What does the discontinued Ozempic package mean?

FDA’s semaglutide resolution materials noted that an older 2 mg/1.5 mL Ozempic presentation was no longer being marketed.

That is another example of why ingredient, brand, and presentation cannot be collapsed into one label:

* Semaglutide injection can be nationally resolved.

* Current Ozempic presentations can be marketed.

* One older presentation can be discontinued.

* Your local pharmacy can still be out.

All four statements can be true at the same time.

What about Ozempic tablets?

Ozempic tablets are a separate dosage form with their own labels, strengths, packages, and supply chain. They should not automatically inherit the injection’s package-level status.

When checking supply, always separate:

* Injection from tablet

* Current package from discontinued package

* Ingredient status from exact NDC

* National status from local availability

---

Is Wegovy in shortage?

Wegovy injection falls under FDA’s February 21, 2025 semaglutide injection shortage resolution and is not in a current national shortage. A particular Wegovy strength can still be difficult to obtain at a pharmacy even when nationwide supply covers nationwide demand.

If you are moving to a new strength and the pharmacy does not have it, do not assume the entire medication has returned to shortage. Ask:

* Is the exact strength out today?

* Can it be ordered?

* Is the wholesaler backordered?

* Does another location have it?

* Is the problem actually insurance authorization or refill timing?

We will not publish a national Wegovy “availability percentage” built from a small number of pharmacy checks. A local sample can describe the locations that were checked. It cannot represent the country unless its design, sample size, geography, selection method, and time window support that claim.

We also will not give one universal answer for how long someone can go between doses. Missed-dose and restart instructions depend on the product labeling and the person’s circumstances. Ask the prescriber or pharmacist before changing the schedule.

---

Are Mounjaro and Zepbound in shortage?

Mounjaro and Zepbound injections are not in a current national tirzepatide injection shortage. FDA removed tirzepatide injection products from the shortage list on October 2, 2024 and, after reevaluating the decision, determined again on December 19, 2024 that the shortage was resolved.

FDA continues to monitor supply and demand.

The reevaluation matters because the December decision was not merely a repeat of the original announcement. FDA reconsidered the shortage determination and reached the same national conclusion.

That still does not mean:

* Every Mounjaro strength is on every shelf.

* Every Zepbound device is locally available.

* A vial result proves a pen result.

* One pharmacy’s backorder represents the entire market.

* An insurance rejection is a supply shortage.

Track each dosage form, device, strength, and package separately. The availability of one presentation does not automatically answer for another.

---

Is Trulicity still in shortage?

Dulaglutide does not appear on FDA’s current active-shortage list checked August 5, 2026. ASHP’s dulaglutide bulletin, updated July 15, 2026, remains filed in its current-shortage system but states that Lilly has Trulicity available and lists the reviewed strengths as available.

That looks strange because the two databases serve different purposes and can retire or maintain records under different criteria and workflows.

The reviewed ASHP bulletin lists available presentations covering:

* 0.75 mg/0.5 mL

* 1.5 mg/0.5 mL

* 3 mg/0.5 mL

* 4.5 mg/0.5 mL

We are summarizing that source rather than reproducing its complete product table.

What is the decision-grade answer?

* FDA’s active list does not currently show dulaglutide as nationally in shortage.

* ASHP’s dated bulletin lists the reviewed Trulicity strengths as available.

* A pharmacy can still encounter a local supply-chain or ordering problem.

* “The entire country has Trulicity” and “my store has none” are not the same claim.

Original RX Index comparison: The database container and the package rows appear to send different signals—“current shortage bulletin” at the page level and “available” at the product level. The product-level result and source date are more useful to a patient than turning the container label into a red brand badge.

If your pharmacy is out, ask it to order your exact strength or check another location before concluding that all Trulicity presentations are nationally unavailable.

---

Was Rybelsus discontinued, and is that different from a shortage?

FDA’s discontinuation database lists Rybelsus 3 mg, 7 mg, and 14 mg packages as manufacturer-reported discontinuations posted June 4, 2026. The record states that these products are being replaced by Ozempic semaglutide tablets.

A discontinuation and a shortage answer different questions.

Shortage: The market temporarily lacks enough supply to meet demand.

Discontinuation: A manufacturer reports that it is ending manufacture of a package.

That is why repeatedly waiting for a discontinued package to “come back in stock” may not solve the problem.

What should someone taking Rybelsus do?

Contact the prescriber before the existing supply is exhausted. Ozempic tablets are a separately labeled product, and the transition must follow the current prescribing information and a valid prescription.

Do not assume that:

* A pharmacy can automatically substitute the new product.

* The milligram numbers translate directly.

* The timing is identical.

* Existing insurance authorization transfers automatically.

* A tablet and an injection can be swapped without clinical direction.

We are deliberately not publishing a conversion schedule. The current FDA-approved labeling and the prescriber or pharmacist should control that decision.

Get help finding the right treatment path

---

What should I do if my GLP-1 dose is out of stock?

Start by confirming that the pharmacy checked your exact brand, dosage form, strength, package, and NDC—not just the ingredient. Then find out whether “unavailable” means out today, wholesaler backorder, unable to order, insurance restriction, or a prescription problem.

Those answers point to different fixes.

The six-step GLP-1 refill plan

1. Get the exact product details

Have these ready:

* Brand

* Ingredient

* Injection or tablet

* Device or package type

* Strength

* Quantity

* NDC, when available

“Semaglutide” is not enough. Ozempic, Wegovy, Rybelsus, and newer semaglutide products can share an ingredient without being interchangeable products.

2. Ask what “unavailable” actually means

The pharmacy may mean:

* Out today, with more expected on the next order

* Backordered by the wholesaler

* Unable to order that NDC

* Unable to fill because of plan restrictions

* Too early to refill

* Prior authorization missing

* Prescription directions or quantity need clarification

* Product discontinued

Do not let five different problems collapse into the word “shortage.”

3. Ask whether the exact package can be ordered

Ask for the product by brand, dosage form, strength, and NDC when possible.

A useful answer is not merely “we do not have it.” A useful answer is:

* Whether it can be ordered

* Which wholesaler response the pharmacy sees

* Whether there is an expected delivery date

* Whether another package of the prescribed product is orderable

* Whether another branch can check inventory

4. Check the insurance channel

Some plans require:

* A specific retail chain

* Mail order

* A specialty pharmacy

* A preferred NDC

* Prior authorization

* A new authorization after a product change

If the problem is the insurance channel, calling unrelated retail pharmacies may waste time.

5. Contact the prescriber before changing anything

Contact the prescriber when:

* The product was discontinued.

* The prescribed presentation cannot be located.

* A different strength or dosage form is being considered.

* A treatment gap has already occurred.

* The pharmacy suggests a different product.

* You are unsure how to resume treatment.

6. Report a suspected broader shortage

FDA accepts reports from patients and health professionals. Include:

* Drug name

* Strength

* Dosage form

* NDC, when known

* Manufacturer, when known

* What the pharmacy reported

* Whether multiple pharmacies gave the same answer

One report does not automatically change national status, but reports can help FDA investigate potential supply problems.

The exact words to use on the phone

“Hi—I have a prescription for [brand], [dosage form], [strength]. Can you check whether that exact product is in stock, whether you can order it from your wholesaler, and whether another location shows it? I am not asking to change the prescription. I need to understand whether this is a store-level issue, a wholesaler backorder, or a product that cannot be ordered.”

That final sentence makes the request specific without asking the pharmacy to make a prescribing decision.

What not to do

* Do not take someone else’s medication.

* Do not buy from an unverified seller.

* Do not change your dose on your own.

* Do not jump ahead in a titration schedule.

* Do not combine doses to create a different dose unless the prescriber and pharmacist explicitly direct it.

* Do not switch between a tablet and an injection without the prescriber.

* Do not assume a local stockout makes a compounded copy lawful or appropriate for you.

* Do not send a shortage-reporting website your prescription number, diagnosis, insurance ID, or medical records unless the service clearly needs them and explains how they will be protected.

Printable refill checklist

* [ ] I have the exact brand.

* [ ] I have the dosage form.

* [ ] I have the exact strength.

* [ ] I have the package quantity.

* [ ] I have the NDC, if available.

* [ ] I asked whether the problem is store stock, wholesaler backorder, insurance, or the prescription.

* [ ] I asked whether the exact package can be ordered.

* [ ] I asked whether another branch can check.

* [ ] I checked my plan’s required pharmacy channel.

* [ ] I contacted my prescriber before changing the product, form, dose, or schedule.

---

Does a local stockout mean I can get compounded semaglutide or tirzepatide again?

No. One pharmacy being out does not return semaglutide injection or tirzepatide injection to FDA’s national shortage list. A local stockout does not by itself restore the shortage-based conditions that supported widespread copying of those FDA-approved drugs.

Compounded drugs are not FDA-approved. FDA does not conduct premarket review of compounded drugs for safety, effectiveness, or quality.

That does not mean every act of patient-specific compounding is categorically prohibited. It means a pharmacy-level stock problem is not enough to conclude that a compounded copy is lawful, appropriate, or equivalent to an FDA-approved product.

What are 503A and 503B compounders?

A 503A pharmacy generally compounds for an identified individual patient based on a valid prescription and must satisfy the applicable conditions of section 503A.

A 503B outsourcing facility can compound larger batches under the conditions of section 503B and is subject to additional federal requirements.

Both pathways contain restrictions relevant to products that are essentially copies of commercially available or FDA-approved drugs.

What happened after the semaglutide and tirzepatide shortages ended?

FDA announced enforcement-policy wind-down periods after resolving the national shortages.

For tirzepatide:

* February 18, 2025 for state-licensed pharmacies or physicians under the stated 503A policy

* March 19, 2025 for outsourcing facilities under the stated 503B policy

For semaglutide:

* April 22, 2025 for state-licensed pharmacies or physicians under the stated 503A policy

* May 22, 2025 for outsourcing facilities under the stated 503B policy

Those temporary periods have passed.

The dates do not mean every possible patient-specific compounded prescription became unlawful on one universal date. They mark the end of FDA’s stated temporary enforcement approach for widespread shortage-driven copying under the circumstances described by the agency.

What is happening with the 503B bulks list?

On April 30, 2026, FDA announced a proposal not to include semaglutide, tirzepatide, or liraglutide on the 503B bulks list, stating that it had not identified a clinical need for outsourcing facilities to compound those drugs from bulk substances.

The formal Federal Register notice was published May 1, 2026.

FDA later extended the comment deadline to July 30, 2026. The comment period is now closed. When checked August 5, 2026, the cited proposal remained a proposal rather than a final published determination.

The Federal Register notice also separates clinical need from ordinary supply problems. It states that FDA does not interpret backorders or similar supply issues as “clinical need” for inclusion on the 503B bulks list. The statute separately addresses shortage-list compounding under its stated conditions.

What does liraglutide’s active shortage mean?

Liraglutide injection remains on FDA’s shortage list. FDA’s 503B framework says outsourcing facilities generally cannot compound from a bulk substance unless the substance is on the 503B bulks list or the compounded drug is on FDA’s shortage list at the relevant times, subject to the other statutory conditions.

That is a regulatory fact—not a recommendation to obtain compounded liraglutide.

The package table also shows why an ingredient-level shortage label is not enough to make a treatment decision. Saxenda and five generic presentations are listed available, while other packages are limited.

Do not use the shortage label as a shopping instruction. A licensed prescriber and dispensing pharmacy must determine what is appropriate and permitted for the individual prescription.

For the full enforcement history, see the compounded GLP-1 enforcement tracker.

---

When should I call my prescriber instead of another pharmacy?

Call the prescriber when the medication, dosage form, strength, schedule, or prescription needs to change. Call the pharmacy when the problem is package identification, ordering, stock, transfer, or another location.

Getting this backward can cost days.

Call the prescriber when…

* The product was discontinued.

* The prescribed presentation cannot be found after a structured pharmacy search.

* You have already missed a scheduled dose.

* You may need a different strength, form, or medication.

* The pharmacy proposes a substitute.

* You are unsure whether or how to restart.

* A new prior authorization or prescription may be needed.

Call the pharmacist when…

* You need the exact NDC.

* You want to know whether the wholesaler can order it.

* You want the pharmacy to check another branch.

* You are asking whether a transfer can be completed.

* You need to know whether the problem is inventory, billing, timing, or prescription directions.

* You want the pharmacy to identify which current package corresponds to the prescription.

What no shortage tracker should generate for you

A shortage tracker should not invent:

* A new dose

* A replacement prescription

* A conversion schedule

* A restart schedule

* A declaration that two products are interchangeable

* Instructions to split, combine, or alter medication

* A promise that a compounded product is equivalent to an FDA-approved drug

If a page gives you those answers without your clinical context, current product labeling, and a licensed professional, close the tab.

---

How do I report a GLP-1 shortage?

Patients and health professionals can report a suspected shortage through FDA’s Drug Shortage Staff reporting system. Include exact product information whenever possible because “GLP-1” or “semaglutide” alone may not identify the affected package.

Useful information includes:

* Brand

* Active ingredient

* Dosage form

* Strength

* Package quantity

* NDC

* Manufacturer

* Pharmacy or wholesaler response

* Date

* Whether more than one pharmacy reported the same issue

FDA evaluates supply nationally. A single local report does not automatically change the official status, but repeated, specific reports can help the agency identify a developing problem.

Report a suspected drug shortage to FDA

What about reporting a local stockout to The RX Index?

The RX Index does not currently publish a local availability score or claim to have a representative national pharmacy sample.

A future local-report system should not launch until it can show:

* Number of unavailable reports

* Number of reported finds

* Total reports or checks

* Reporting window

* Geographic coverage

* Most recent report

* Duplicate-control method

* Moderation method

* Clear separation from FDA status

Until those controls exist, no local percentage belongs on this page.

---

How often is this GLP-1 shortage tracker updated?

FDA source records can change at any time, and each manufacturer’s information can carry a different reverification date. The RX Index checks the active FDA status frequently, performs a full claim-by-claim review monthly, and changes the visible “Last verified” date only after the data has actually been rechecked.

A design edit or typo fix does not earn a new verification date.

Change log

* August 5, 2026 — Full factual and compliance audit completed. Hikma’s reverification date corrected to July 13, 2026. Database-absence claims narrowed. Unimplemented local-report, alert, and downloadable-data promises removed.

* July 30, 2026 — Extended federal comment period closed on FDA’s proposal concerning semaglutide, tirzepatide, and liraglutide for the 503B bulks list.

* July 15, 2026 — ASHP dulaglutide bulletin updated and reviewed.

* July 13, 2026 — Hikma liraglutide package information reverified in FDA’s current record.

* June 8, 2026 — Novo Nordisk liraglutide information reverified: Saxenda available and two Victoza packages limited.

* June 4, 2026 — Rybelsus 3 mg, 7 mg, and 14 mg discontinuations posted in FDA’s database.

* June 1, 2026 — Meitheal liraglutide information reverified; one package remained limited with a July 2026 recovery estimate.

---

How did The RX Index build and verify this tracker?

We separate national status, package status, and local availability because combining them produces misleading answers. Every consequential status is tied to a primary source, an exact product or NDC when available, and a verification date.

Source order

1. FDA national shortage determinations for whether a national shortage is active or resolved.
2. FDA package-level and discontinuation records for manufacturer, presentation, NDC, availability, and dates.
3. Current FDA-approved product labeling for dosage-form and product distinctions.
4. Manufacturer supply statements for current manufacturer-reported information.
5. ASHP bulletins as dated, attributed clinician-facing cross-checks.
6. First-party local reports, only after a transparent methodology and adequate data exist.
7. Other trackers, used for research but not republished as The RX Index facts.
8. Forums and social posts, used only to understand language and frustration—not as medical or supply evidence.

What we actually verified

Verified August 5, 2026:

* Liraglutide injection remains listed by FDA as Currently in Shortage.

* The FDA record contains nine package rows.

* Six rows are marked Available.

* Three rows are marked Limited Availability.

* Saxenda NDC 0169-2800-15 is listed Available.

* Both listed Victoza NDCs are marked Limited Availability because of shipping delays.

* Hikma’s current manufacturer reverification date is July 13, 2026.

* Meitheal’s manufacturer reverification date is June 1, 2026.

* Novo Nordisk’s manufacturer reverification date is June 8, 2026.

* The Meitheal July 2026 estimated recovery date passed without a newer confirmation displayed in the reviewed FDA record.

* FDA resolved the semaglutide injection shortage on February 21, 2025.

* FDA reaffirmed the tirzepatide injection shortage resolution on December 19, 2024.

* FDA lists manufacturer-reported discontinuations for Rybelsus 3 mg, 7 mg, and 14 mg posted June 4, 2026.

* Dulaglutide does not appear on FDA’s active shortage list checked August 5, 2026.

* ASHP’s July 15, 2026 dulaglutide bulletin states that Lilly has Trulicity available and lists the reviewed presentations as available.

* FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list.

* The extended comment period closed July 30, 2026.

* The cited proposal had not been replaced by a final determination when reviewed.

What we did not verify

* Shelf inventory at any individual pharmacy.

* A nationwide local-availability percentage.

* Whether an insurer will cover a particular fill.

* Whether a specific alternative medication is appropriate for an individual.

* Whether the Meitheal package recovered after the displayed July estimate.

* Whether every pharmacy can search another branch’s inventory.

* Whether a transfer is allowed in every situation.

* Any local-reporting feature, dose-status alert, or downloadable CSV on The RX Index.

Corrections

See something wrong? Send the exact source, drug, package, NDC, and date involved. Consequential corrections are checked against a primary source before the public status changes.

---

Frequently asked questions about the GLP-1 shortage tracker

Is there still a GLP-1 shortage in 2026?

Yes, but not for every GLP-1. Liraglutide injection is currently listed by FDA as being in shortage. Semaglutide injection and tirzepatide injection have national shortage-resolution determinations.

Which GLP-1 is currently in shortage?

Liraglutide injection. Its products do not share one package-level result: Saxenda and five generic packages are listed available, while two Victoza packages and one Meitheal generic package are listed as having Limited Availability.

Does “Available” mean my pharmacy has it?

No. It reflects the package-level information displayed in FDA’s record. It is not a live check of a pharmacy shelf.

Why does FDA not show every local stockout?

FDA determines whether national supply covers national demand. A store-level stockout may be caused by distribution, ordering, wholesaler, insurance, or prescription issues without becoming a national shortage.

Is Saxenda in shortage?

Liraglutide injection is nationally in shortage, but the Saxenda package in FDA’s current record is marked Available. Your pharmacy can still be locally out.

Is Victoza in shortage?

FDA lists the two reviewed Victoza packages as having Limited Availability because of shipping delays. The record gives no recovery date and lists the duration as TBD.

Is Ozempic still in shortage?

No national semaglutide injection shortage is active under FDA’s February 21, 2025 determination. Local pharmacy gaps can still occur.

Is Wegovy still in shortage?

Wegovy injection falls under the resolved semaglutide injection shortage determination. A particular strength can still be temporarily unavailable locally.

Are Mounjaro and Zepbound in shortage?

No national tirzepatide injection shortage is active under FDA’s December 19, 2024 reevaluation. Package-specific and local access can still vary.

Is Trulicity still in shortage?

Dulaglutide does not appear on FDA’s current active-shortage list. ASHP’s July 15, 2026 dulaglutide bulletin remains in its shortage system but states that Lilly has Trulicity available and lists the reviewed presentations as available.

Was Rybelsus discontinued?

FDA’s discontinuation database lists Rybelsus 3 mg, 7 mg, and 14 mg packages as manufacturer-reported discontinuations posted June 4, 2026. The record says those products are being replaced by Ozempic semaglutide tablets.

How long can I go without my GLP-1 dose?

There is no universal answer. Missed-dose and restart instructions differ by product and circumstance. Ask the prescriber or pharmacist and use the current FDA-approved labeling.

Can I switch to another dose or GLP-1 if mine is unavailable?

Not on your own. A different dose, dosage form, device, or drug can require a new clinical decision and prescription.

Can I get compounded semaglutide because my pharmacy is out?

A local stockout does not put semaglutide injection back on FDA’s national shortage list or automatically reopen shortage-based copying. Compounded drugs are not FDA-approved.

Is this tracker real-time?

No. FDA status is checked frequently, supporting sources carry their own dates, and the full page is manually audited monthly. The RX Index does not claim direct pharmacy inventory.

Does this tracker cover countries outside the United States?

No. The status framework and sources on this page are United States-specific.

---

If you have decided it is time to find a different treatment path

Some people did not reach this page because one pharmacy was out for a day. They reached it because their product was discontinued, their refill has failed repeatedly, their insurance channel changed, or they no longer trust the path they were using.

If that is your situation, you do not need a harder sales pitch. You need the path separated correctly.

If you want an FDA-approved medication

Use a treatment path that clearly identifies the FDA-approved product, its current price, insurance process, pharmacy channel, and membership cost. Do not let a provider blur an FDA-approved brand with a compounded medication.

If you are considering a compounded medication

Compounded medications are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or quality. Ask who prescribes the medication, which pharmacy compounds it, what formulation is being prescribed, what the complete price includes, and what happens if the treatment or regulatory environment changes.

If you do not know which description fits you

Do not choose from a random two-provider list. State availability, insurance, formulary rules, FDA-approved versus compounded preference, dosage form, clinical fit, and budget can all change the answer.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

---

Sources

All sources were last checked August 5, 2026 unless another date is stated.

1. FDA Drug Shortages Database—Current and Resolved Drug Shortages and Discontinuations
2. FDA Drug Shortages—Liraglutide Injection, Currently in Shortage
3. FDA Drug Shortages—Semaglutide Tablet Discontinuations
4. FDA Declaratory Order—Resolution of Semaglutide Injection Product Shortage, February 21, 2025
5. FDA—Resolution of Tirzepatide Injection Product Shortage and Supply Status, December 19, 2024
6. FDA—Policies for Compounders as National GLP-1 Supply Stabilized
7. FDA—Compounding and FDA: Questions and Answers
8. FDA—Proposal Concerning Semaglutide, Tirzepatide, and Liraglutide on the 503B Bulks List
9. Federal Register—May 1, 2026 Proposed 503B Bulks-List Determination
10. Federal Register—June 26, 2026 Comment-Period Extension
11. ASHP—Dulaglutide Injection Bulletin, updated July 15, 2026
12. FDA—Frequently Asked Questions About Drug Shortages

---

Medical disclaimer

This page provides general information about medication-supply status. It is not medical advice and is not a substitute for a prescriber or pharmacist. It has not been reviewed by a clinician. Do not change, stop, restart, combine, split, or adjust medication based on this page. Talk to a licensed healthcare professional about your situation.